IP Library Granted Patent US 11,655,492
Granted Patent B2
US 11,655,492 · App. 17/336,975 · Granted May 23, 2023

Activated formylglycine-generating enzymes and methods of producing and using the same

Inventors: David Rabuka (Kensington, CA); Gregory W. deHart (Emeryville, CA); Patrick Holder (Oakland, CA); Jeanne Baker (Redwood City, CA)
Assignee: R.P. Scherer Technologies, LLC
C12P21/005A61K47/68A61K47/6889C07K16/00C07K16/32C12N9/0051C12P21/00C07K2317/14C07K2317/40C12Y108/99
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,655,492
App. No.
17/336,975
Granted
May 23, 2023
Kind
B2
Abstract

The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.

Claims (16)

1. An activated formylglycine-generating enzyme (FGE) produced by a method comprising treating an FGE with Cu 2+ to produce an activated FGE.

2. A cell-free composition comprising:

an activated formylglycine-generating enzyme (FGE); and

a buffer.

3. The composition of claim 2 , further comprising a protein comprising an FGE recognition site.

4. The composition of claim 2 , wherein the FGE is an N-terminally truncated FGE.

5. The composition of claim 4 , wherein the FGE is a N-terminally truncated human FGE.

6. A kit comprising:

an activated formylglycine-generating enzyme (FGE); and

instructions for using the activated FGE to convert a cysteine residue or a serine residue present in an FGE recognition site of a protein to a formylglycine residue.

7. The kit of claim 6 , wherein the FGE is an N-terminally truncated FGE.

8. The kit of claim 7 , wherein the FGE is a N-terminally truncated human FGE.

9. A kit comprising:

a nucleic acid that encodes a formylglycine-generating enzyme (FGE); and

Cu 2+ or a source of Cu 2+ .

10. The kit of claim 9 , further comprising cells suitable for expressing the FGE encoded by the nucleic acid.

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: RABUKA, DAVID; DEHART, GREGORY W.; HOLDER, PATRICK; BAKER, JEANNE
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 057372/0161 →